As Roche heads towards an FDA verdict on its CD20xCD3 bispecific Lunsumio for lymphoma before the end of this year, rivals from Regeneron and AbbVie are starting to nip at its heels, with n
Roche will present the new data at next week's ASCO congress showing that its bispecific antibody glofitamab can achieve high and durable responses in patients with aggressive lymphoma.
A subcutaneous formulation of MSD's top-selling cancer immunotherapy Keytruda was non-inferior to the current intravenous version in a head-to-head trial, setting up regulatory filings.
